Actively Recruiting
Study of Dupilumab and Narrowband UVB Phototherapy for Moderate-to-Severe Atopic Dermatitis in Adults
Led by Psoriasis Treatment Center of Central New Jersey · Updated on 2024-03-15
40
Participants Needed
1
Research Sites
2 weeks
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate the combination of dupilumab and narrowband UVB phototherapy for adults with moderate to severe atopic dermatitis. The study is a 24-week open-label trial sponsored by the Psoriasis Treatment Center of Central New Jersey, focusing on the safety and effectiveness of these treatments in improving skin condition. Participants will receive dupilumab 300mg along with narrowband UVB phototherapy three times a week for the first 12 weeks. Following this, they will continue with dupilumab alone for an additional 12 weeks. This treatment plan allows researchers to observe the effects of combined therapy followed by monotherapy. During the study, participants will be monitored for changes in their skin using the Investigators Global Assessment Score at 12 weeks. Researchers will assess skin improvements and monitor safety throughout the 24 weeks. Participants can expect regular visits for treatment and evaluations to track progress and any side effects.
CONDITIONS
Brief Title
Dupixent and Narrowband UVB for Atopic Dermatitis
Research Team
E
Elise Nelson
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
